
## Giacomo Gorini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8556348/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	30.7	265
2	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	30.7	473
3	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. IScience, 2021, 24, 102047.	4.1	16
4	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	13.7	2,080
5	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	13.7	1,196
6	The V2 loop of HIV gp120 delivers costimulatory signals to CD4 <sup>+</sup> T cells through Integrin α <sub>4</sub> β <sub>7</sub> and promotes cellular activation and infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32566-32573.	7.1	14
7	Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. PLoS Pathogens, 2020, 16, e1008377.	4.7	14
8	ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. PLoS Pathogens, 2019, 15, e1008121.	4.7	19
9	Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to î±4î²7. PLoS Pathogens, 2018, 14, e1007278.	4.7	29
10	HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. Nature Medicine, 2018, 24, 847-856.	30.7	65
11	The sudden death of Alaric I (c. 370–410AD), the vanquisher of Rome: A tale of malaria and lacking immunity. European Journal of Internal Medicine, 2016, 31, 84-87.	2.2	8
12	Regulatory and Helper Follicular T Cells and Antibody Avidity to Simian Immunodeficiency Virus Glycoprotein 120. Journal of Immunology, 2015, 195, 3227-3236.	0.8	31
13	Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections. BioMed Research International, 2013, 2013, 1-21.	1.9	15
14	Anti-V2 Antibodies Virus Vulnerability Revealed by Envelope V1 Deletion in HIV Vaccine Candidates. SSRN Electronic Journal, 0, , .	0.4	0